{'fraction_non_alphanumeric': 0.03517662289624561, 'fraction_numerical': 0.0254115036064361, 'mean_word_length': 5.161349134001823, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 1, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling

Lymphatic metastasis constitutes a leading cause of recurrence and mortality in bladder cancer. Accumulating evidence indicates that lymphangiogenesis is indispensable to trigger lymphatic metastasis. However, the specific mechanism is poorly understood. In the present study, we revealed a pathway involved in lymphatic metastasis of bladder cancer, in which a circular RNA (circRNA) facilitated lymphangiogenesis in a vascular endothelial growth factor C (VEGF-C)-independent manner. Novel circRNA circEHBP1 was markedly upregulated in bladder cancer and correlated positively with lymphatic metastasis and poor prognosis of patients with bladder cancer. circEHBP1 upregulated transforming growth factor beta receptor 1 (TGFBR1) expression through physically binding to miR-130a-3p and antagonizing the suppression effect of miR-130a-3p on the 3′ UTR region of TGFBR1. Subsequently, circEHBP1-mediated TGFβR1 overexpression activated the TGF-β/SMAD3 signaling pathway, thereby promoting the secretion of VEGF-D and driving lymphangiogenesis and lymphatic metastasis in bladder cancer. Importantly, administration of VEGF-D neutralizing antibodies remarkably blocked circEHBP1-induced lymphangiogenesis and lymphatic metastasis in vivo. Our findings highlighted that the circEHBP1/miR-130a-3p/TGFβR1/VEGF-D axis contributes to lymphangiogenesis and lymphatic metastasis of bladder cancer independent of VEGF-C, which might lead to the development of circEHBP1 as a potential biomarker and promising therapeutic target for lymphatic metastasis in bladder cancer.

Lymphatic metastasis constitutes a leading cause of recurrence and mortality in bladder cancer. Accumulating evidence indicates that lymphangiogenesis is indispensable to trigger lymphatic metastasis. However, the specific mechanism is poorly understood. In the present study, we revealed a pathway involved in lymphatic metastasis of bladder cancer, in which a circular RNA (circRNA) facilitated lymphangiogenesis in a vascular endothelial growth factor C (VEGF-C)-independent manner. Novel circRNA circEHBP1 was markedly upregulated in bladder cancer and correlated positively with lymphatic metastasis and poor prognosis of patients with bladder cancer. circEHBP1 upregulated transforming growth factor beta receptor 1 (TGFBR1) expression through physically binding to miR-130a-3p and antagonizing the suppression effect of miR-130a-3p on the 3 0 UTR region of TGFBR1. Subsequently, cir-cEHBP1-mediated TGFbR1 overexpression activated the TGF-b/SMAD3 signaling pathway, thereby promoting the secretion of VEGF-D and driving lymphangiogenesis and lymphatic metastasis in bladder cancer. Importantly, administration of VEGF-D neutralizing antibodies remarkably blocked circEHBP1-induced lymphangiogenesis and lymphatic metastasis in vivo. Our findings highlighted that the circEHBP1/ miR-130a-3p/TGFbR1/VEGF-D axis contributes to lymphangiogenesis and lymphatic metastasis of bladder cancer independent of VEGF-C, which might lead to the development of cir-cEHBP1 as a potential biomarker and promising therapeutic target for lymphatic metastasis in bladder cancer.

INTRODUCTION
Bladder cancer (BCa) is one of the ten most common malignancies, with an estimated 430,000 new diagnosed patients and over 170,000 deaths worldwide annually. 1 The presence of lymph node (LN) metastasis is a potently pathological predictor of poor prognosis in BCa, accompanied by a reduction of the average 5-year survival rate to merely 18.6%. 2,3 Emerging evidence illustrates that lymphangiogenesis, which refers to the formation of new lymphatic vessels from the preexisting lymphatics, intratumorally and peritumorally, promotes the process of LN metastasis. 4,5 Despite the crucial role that lymphangiogenesis plays in LN metastasis of human cancer, the underlying mechanism of lymphangiogenesis in BCa is poorly understood.
Lymphangiogenesis is stimulated by identified lymphangiogenic factors, in particular, vascular endothelial growth factor (VEGF)-C and VEGF-D, which are dedicated to the growth of lymphatic vessels. 6 Recently, VEGF-D was validated to facilitate lymphangiogenesis and LN metastasis in multiple cancers. 7 In addition, it has been reported that VEGF-D neutralizing antibodies could decrease the spread of tumor cells to LNs by inhibiting the dilation of the lymphatic collecting duct. 8 Therefore, VEGF-D might be a novel indicator for LN metastasis in malignant tumors, and the role of VEGF-D in LN metastasis of BCa should be investigated urgently.
The transforming growth factor beta receptor 1 (TGFbR1), a serine/ threonine kinase receptor, mainly works as the central signal transducer of the TGF-b signaling pathway by phosphorylating the downstream protein SMAD2/3 and promotes the malignant progression of cancers. 9 Numerous studies have verified that TGFbR1 acts as a critical metastatic promoter to enhance the colonization of distant organs by cancer cells. 10 Further analysis revealed that TGFbR1 induced LN metastasis of human cancers and that blocking the TGF-b signaling pathway was a potential target to treat cancers. 11,12 Nevertheless, the precise regulatory mechanism that induces TGFbR1 to promote lymphangiogenesis and LN metastasis of BCa remains unclear.
Circular RNAs (circRNAs), a class of single-stranded molecules with development-specific expression patterns, are characterized by a covalently closed structure and generated from the back-splicing of pre-mRNA transcripts. Differing from linear RNAs, circRNAs contain neither 5 0 -3 0 polarity nor a polyadenylation tail. 13,14 Accumulating studies have reported that circRNAs are widely detected in a variety of cancers and play an indispensable regulatory role in tumor development and progression. 15,16 Herein, we report a novel circRNA, circEHBP1 (hsa_circ_0005552), which was markedly upregulated in BCa and correlated positively with the prognosis of patients with BCa. circEHBP1 overexpression induced lymphangiogenesis and LN metastasis of BCa in vitro and in vivo. Mechanistically, cir-cEHBP1 overexpression promoted TGFbR1 expression by attenuating miR-130a-3p to activate the TGF-b/SMAD3 signaling pathway, further elevating VEGF-D secretion and ultimately facilitating lymphangiogenesis and LN metastasis of BCa. Our findings revealed a VEGF-C-independent mechanism of circEHBP1-mediated lymphangiogenesis of BCa and implied circEHBP1 is a potential therapeutic target to treat LN metastasis in BCa.

circEHBP1 is correlated with LN metastasis in BCa
To identify the critical circRNAs involved in the LN metastasis of BCa, 47 upregulated circRNAs (fold change R 2.0 and p < 0.05) were screened from RNA sequencing data (GEO: GSE77661) 17 of BCa tissue and normal adjacent tissue (NAT). Then, the elevated circRNAs were validated in the previously established invasion model of BCa cell lines, and 23 invasion-related circRNAs were selected (Figures 1A and 1B). Previously, we verified that VEGF-C is a key inducer for LN metastasis of BCa. 18 However, a few patients with BCa with LN metastasis possess low VEGF-C expression, 19,20 indicating the presence of a VEGF-C-independent mechanism for LN metastasis of BCa. Thus, the top 10 ranked circRNAs from the above screening according to their fold changes were further evaluated in 17 LN-positive BCa tissues with low VEGF-C expression, which showed that cir-cEHBP1 (hsa_circ_0005552) was the most significantly upregulated circRNA; therefore, we chose circEHBP1 for further study ( Figure 1C; Table S1).
Next, we studied the role of circEHBP1 in BCa. First, we found that higher circEHBP1 levels were detected in UM-UC-3, T24, and 5637 cells (BCa cells) compared with those in SV-HUC-1 cells (human uroepithelial cells) ( Figure 1D). Further analysis in a cohort of 186 cases of BCa showed that circEHBP1 was overexpressed in BCa tissues and was associated positively with LN metastasis and the pathological grades of patients with BCa ( Figures 1E-1G; Figures S1A-S1C; Table  1). Moreover, circEHBP1 expression was higher in metastatic LNs compared with that in primary tumors ( Figure 1H; Figure S1D). Kaplan-Meier analysis revealed that circEHBP1 expression associated negatively with overall survival (OS) and disease-free survival (DFS) in patients with BCa ( Figures 1I and 1J). Univariate and multivariate analyses indicated that poor prognosis of patients with BCa was independently affected by circEHBP1 (Tables S2 and S3). In situ hybridization (ISH) analysis showed that the lymphatic vessel density (LVD) in BCa tissues correlated positively with circEHBP1 expression (Figures 1K and 1L). Taken together, these results indicated that circEHBP1 is associated with LN metastasis of BCa.
Characteristics of circEHBP1 in BCa cells circEHBP1 was derived from exon 15 to exon 19 of the EHBP1 gene (encoding EH domain binding protein 1) with a length of 751 nucleotides (nt), in which the back-spliced junction was confirmed using Sanger sequencing ( Figures 1M and 1N). Moreover, circEHBP1 could only be amplified from the complementary DNA (cDNA) rather than the genomic DNA (gDNA) (Figures 1O and 1P). Compared with the results using random primers, circEHBP1 expression was scarcely detected using oligo-dT primers, indicating that circEHBP1 lacked a poly-A tail ( Figure 1Q). circRNAs exhibit higher stability than their linear counterparts; therefore, we further studied the stability of circEHBP1. The results showed that circEHBP1 was resistant to RNase R compared with linear EHBP1 mRNA (mEHBP1) or linear control GAPDH ( Figure 1R; Figures S1E and S1F). The half-life of circEHBP1 was longer than that of mEHBP1 after treatment with actinomycin D, which blocks de novo RNA synthesis ( Figures 1S and 1T). The above results illustrated that circEHBP1, as a circRNA, possesses high stability.

circEHBP1 promotes lymphangiogenesis of BCa in vitro
Lymphangiogenesis is identified as a considerable step of LN metastasis; therefore, we further explored the effect of circEHBP1 on lymphangiogenesis of BCa in vitro. circEHBP1 was successfully downregulated through transfection with small interfering RNAs (siRNAs) that targeted the head-to-tail splicing region of circEHBP1 and upregulated after transfection with circEHBP1-overexpressing plasmid. No significant changes in mEHBP1 expression were observed (Figures 2A-2D). The in vitro assay showed that circEHBP1 knockdown in UM-UC-3 and T24 cells dramatically abolished their ability to induce tube formation and migration of human lymphatic endothelial cells (HLECs), while circEHBP1 overexpression facilitated UM-UC-3 and T24 cells to drive HLEC tube formation and migration ( Figures 2E-2P). In addition, although Cell Counting Kit-8 (CCK-8) and colony formation assays showed that circEHBP1 knockdown inhibited the proliferation of UM-UC-3 and T24 cells and circEHBP1 overexpression promoted their proliferation ability (Figures S1G-S1N), the alteration of circEHBP1 expression had no significant effect on the invasiveness of BCa cells, which further verified that cir-cEHBP1 played a crucial role in LN metastasis through facilitating the lymphangiogenesis. Collectively, these findings suggested that cir-cEHBP1 triggers lymphangiogenesis of BCa in vitro.

circEHBP1 facilitates LN metastasis of BCa in vivo
To further investigate the role of circEHBP1 in LN metastasis in vivo, we constructed a popliteal lymph node metastatic model through the inoculation of luciferase-labeled vector or circEHBP1-overexpressing UM-UC-3 cells into the right footpads of nude mice ( Figure 3A). LN metastatic status was measured when the footpad tumors reached about 200 mm 3 . The in vivo imaging systems (IVIS) results indicated that the fluorescence intensity was remarkably increased in the cir-cEHBP1-overexpressing group, and the volume of popliteal LNs was larger after circEHBP1 overexpression ( Figures 3B-3E). Furthermore, the LN metastatic rate was higher in the circEHBP1-overexpressing group compared with that of the control group ( Figure 3F). The ISH assay showed that circEHBP1 improved LVD in the primary tumor tissues, and survival analysis suggested that circEHBP1 shortened the survival of the mice (Figures 3G-3I). Taken together, these results indicated that circEHBP1 facilitates LN metastasis of BCa in vivo.

circEHBP1 sponges miR-130-3p in BCa cells
Given that the distinct function of RNAs is based upon their subcellular localization, we next analyzed the localization of circEHBP1 in BCa cells. Fluorescence in situ hybridization (FISH) and subcellular fractionation assays demonstrated that circEHBP1 was primarily located in the cytoplasm of BCa cells (Figures 4A and 4B; Figure S2A). Cytoplasm-located circRNAs contain multiple microRNA (miRNA)binding sites and mainly act as miRNA sponges. 21,22 Therefore, 10 candidate miRNAs that potentially bound to circEHBP1 were predicted using RegRNA 2.0 (http://regrna2.mbc.nctu.edu.tw/) 23 (Figure 4C). Only miR-130a-3p was enriched by circEHBP1 in an RNA pull-down assay ( Figures 4D and 4E). The miR-130a-3p binding site of circEHBP1 was predicted using RNAalifold (http://rna.tbi. univie.ac.at/) and then mutated to conduct dual-luciferase reporter assays ( Figures 4F and 4G). The result revealed that the luciferase activity of circEHBP1-wild-type (WT) was significantly reduced by miR-130a-3p, while circEHBP1-mut was not affected, supporting that this specific region was essential for the sponging effect of cir-cEHBP1 on miR-130a-3p ( Figure 4H; Figure S2B). Consistently, a pull-down assay with a biotin-labeled miR-130a-3p probe found that circEHBP1 was captured by miR-130a-3p ( Figure 4I). Moreover, a FISH assay showed the colocalization of circEHBP1 and miR-130a-3p in the cytoplasm of UM-UC-3 and T24 cells ( Figure 4J). Collectively, these findings verified that circEHBP1 sponges miR-130-3p in BCa.
circEHBP1 upregulates TGFbR1 to activate the TGF-b/SMAD signaling pathway in BCa To explore the downstream targets of miR-130a-3p, TargetScan (http://www.targetscan.org/) 24 and miRTarBase (http://mirtarbase. mbc.nctu.edu.tw/) 25 were applied, and the predicted genes were intersected to acquire 76 genes for the further analysis in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. 26 The results showed that the TGF-b signaling pathway ranked highest among the enriched pathways ( Figures S3A and S3B). Furthermore, quantitative real-time reverse transcription PCR (RT-PCR) and western blotting analysis revealed that only TGFbR1 expression correlated negatively with miR-130a-3p ( Figures S3C-S3J). miRNAs exert their regulatory roles by binding to the 3 0 UTR region of target genes; 27 therefore, we analyzed the sequences of miR-130a-3p and TGFBR1 3 0 UTR region and found specific sequences within the 3 0 UTR region of TGFBR1 that were complementary to miR-130a-3p ( Figure 5E). Dual-luciferase assays revealed that the luciferase activity of TGFBR1-WT was notably reduced by miR-130a-3p, whereas no obvious change was found after mutating the miR-130a-3p binding site in the TGFBR1 3 0 UTR ( Figures 5F and 5G). Therefore, TGFBR1 is the downstream target of miR-130a-3p.
circEHBP1 drives lymphangiogenesis via a VEGF-D-dependent mechanism VEGF-C is pivotal for the induction of lymphangiogenesis. Previously, we verified the essential role of VEGF-C in lymphangiogenesis of BCa. 28 Nevertheless, some patients with LN metastatic BCa exhibited low VEGF-C expression, 19,20 indicating the presence of a VEGF-C-independent mechanism of inducing lymphangiogenesis in BCa. VEGF-D has been reported to play a compensatory role in lymphatic sprouting in animals with VEGF-C deficiency. 29 Therefore, we explored whether VEGF-D was involved in circEHBP1-induced lymphangiogenesis of BCa. VEGF-D levels were reduced by downregulating circEHBP1 and enhanced by upregulating circEHBP1 in BCa cells ( Figures 6A and 6B). Consistent results were also obtained using an enzyme-linked immunosorbent assay (ELISA), indicating that cir-cEHBP1 regulates VEGF-D expression positively ( Figures 6C and  6D). Furthermore, inhibiting the TGF-b/SMAD3 signaling pathway using the TGFbR1 inhibitor LY364947 significantly abrogated cir-cEHBP1-mediated VEGF-D expression (Figures 6E-6H). Moreover, treatment with VEGF-D neutralizing antibodies weakened the tube formation and migration ability of HLECs induced by circEHBP1 ( Figure 6I; Figures S4A-S4C). The in vivo assay showed that the cir-cEHBP1-induced increase in the volume and metastatic ratio of LNs was reduced by neutralizing VEGF-D, accompanied by prolonged survival (Figures 6J-6L). Importantly, immunohistochemistry (IHC) analysis revealed that circEHBP1 overexpression significantly increased the VEGF-D expression and the quantities of lymphatic vessels in footpad tumors, which were decreased by VEGF-D neutralization ( Figures 6M-6O). Thus, our findings illustrated that cir-cEHBP1 drives lymphangiogenesis by activating the TGF-b/ SMAD3 signaling pathway and increasing VEGF-D secretion in BCa.
Clinical relevance of the circEHBP1/miR-130a-3p/TGFBR1/ VEGF-D axis in patients with BCa circEHBP1 mediates the miR-130a-3p/TGFBR1/VEGF-D axis and contributes to LN metastasis of BCa; therefore, we examined the clinical relevance of this regulatory axis in a cohort of 186 patients with BCa. The results showed that miR-130a-3p was downregulated and SMAD3, TGFBR1, and VEGF-D were upregulated in BCa tissues compared with NATs. Moreover, miR-130a-3p was correlated negatively with LN metastatic status and the pathological grade, while TGFBR1 and VEGF-D overexpression were associated with the LN metastasis of patients with BCa, suggesting their crucial roles in LN metastasis of BCa ( Figures 7A-7E; Figures S4D-S4F). In addition, Kaplan-Meier analysis revealed that miR-130a- ( Figures 7F and 7G). Furthermore, correlation analysis showed a negative correlation between circEHBP1 and miR-130a-3p in BCa and revealed that both TGFBR1 and VEGF-D expression correlated positively with circEHBP1 expression and negatively with miR-130a-3p expression in BCa (Figures S4G-S4I; Figures 7H and 7I). Taken together, our results revealed that circEHBP1 induces the miR-130a-3p/TGFBR1/VEGF-D axis to facilitate LN metastasis in BCa.

DISCUSSION
Lymphangiogenesis is believed to be indispensable for LN metastasis, which is responsible for the poor prognosis of patients with BCa. 30 Although VEGF-C is a key regulator in the lymphangiogenesis associated with human cancer, further investigation showed that a subset of patients with BCa with LN metastasis have a low level of VEGF-C; 19,20 however, there has been little research implicating a VEGF-C-independent mechanism of regulating LN metastasis in BCa. In the present study, we revealed a novel mechanism whereby circEHBP1 induces lym-phangiogenesis of BCa in a VEGF-C-independent manner. cir-cEHBP1 was overexpressed in BCa tissues and attenuated the endogenous inhibitory impact of miR-130a-3p on its downstream target TGFbR1, which further activated the TGF-b/ SMAD3 signaling pathway to induce the expression of VEGF-D and promoted lymphangiogenesis and LN metastasis of BCa. To the best of our knowledge, this is the first report to illustrate a VEGF-C-independent mechanism regulated by cir-cEHBP1 in lymphangiogenesis of BCa and might support cir-cEHBP1 as a new intervention target for LN metastasis in BCa. The co-localization of circEHBP1 and miR-130a-3p was detected by FISH assay. Scale bar, 100 mm. Two-tailed Student's t test or 1-way analyses of variance were used to determine the significance level, and Dunnett's test was used for multiple comparisons. Error bars indicate standard deviations. *p < 0.05, **p < 0.01.

VEGF-D was reported to play a facilitative role in lymphangiogenesis
in an in vivo model with low VEGF-C levels. 29,31 VEGF-D drives the formation of new lymphatic vessels via binding to vascular endothelial growth factor receptor 3 (VEGFR-3) and promoting LN metastasis. 32,33 However, the specific contribution of VEGF-D in lymphangiogenesis and LN metastasis of BCa remains unknown. In the present study, we demonstrated that VEGF-D overexpression contributes to lymphangiogenesis and LN metastasis of BCa, and blocking VEGF-D with neutralizing antibody markedly suppressed cir-cEHBP1-induced lymphangiogenesis in BCa, indicating that VEGF-D functions as a vital inducer of lymphangiogenesis. Importantly, studies have reported a VEGF-D-driven induction of dilated lymphatic vessels and stimulation of LN metastasis in multiple tumors, 34,35 whereas how VEGF-D expression is regulated in LN metastasis of BCa remains elusive. In the present study, we confirmed that circEHBP1 induced the upregulation of VEGF-D, which promoted TGFbR1 overexpression and activation of the TGF-b/SMAD3 signaling pathway. Thus, our results revealed a regulatory mechanism of circEHBP1-induced VEGF-D expression in lymphangiogenesis and might provide insights into the regulation of LN metastasis in BCa.
Another valuable finding in our study is that TGFbR1 was remarkably upregulated in BCa with LN metastasis. TGFbR1 contributes to LN metastasis in several cancers by serving as a vital serine/threonine kinase receptor in the TGF-b/SMAD3 pathway. 36,37 Upregulation of TGFbR1 induced LN metastasis in breast cancer cells. 38 Moreover, the application of a TGFbR1 inhibitor suppressed lymphangiogenesis and LN metastasis in pancreatic cancer. 39 However, whether TGFbR1 is involved in the progression of LN metastasis in BCa remains unknown. In this study, we showed that the expression of TGFBR1 was inhibited by miR-130a-3p via binding to the 3 0 UTR of TGFBR1. circEHBP1 antagonized the inhibition of TGFBR1 by miR-130a-3p and activated the TGF-b/SMAD3 signaling pathway to promote LN metastasis of BCa. Furthermore, inactivating the TGF-b/SMAD3 signaling pathway using the TGFbR1 inhibitor LY364947 eliminated the circEHBP1-mediated increase in VEGF-D expression. Collectively, our study expanded our knowledge of the role played by TGFbR1 in the LN metastasis of BCa.
Recent reports have identified circRNAs as promising targets for clinical application due to their abundance, high stability, and unique expression pattern. 13,14,40 Endogenous circRNAs from the host and exogenous circRNAs encoded by viruses contribute to the prevention of viral infections. 41 Nonetheless, little is known about the potential therapeutic role played by circRNAs in patients with BCa with LN metastasis. In the present study, we demonstrated that circEHBP1 was highly expressed in samples from patients with BCa with LN metastasis. Additionally, we found that circEHBP1 overexpression effectively promoted popliteal LN metastasis in nude mice, indicating that circEHBP1 was a potential therapeutic target for LN metastasis in BCa. Thus, circEHBP1 facilitates LN metastasis in BCa and represents a new target for intervention strategies to treat LN metastasis in patients with BCa.

Conclusions
In summary, we revealed a novel pathway in which circEHBP1 increases the secretion of VEGF-D to facilitate lymphangiogenesis and LN metastasis in BCa, independent of VEGF-C. Clinically, cir-cEHBP1 overexpression correlated closely with LN metastasis. Our study supports circEHBP1 as a potential biomarker and therapeutic target for LN metastasis in patients with BCa.

MATERIALS AND METHODS
Additional materials and methods can be found in the Supplemental information. cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, CA, USA), T24 and 5637 cells were cultured in 1640 medium (Gibco), and SV-HUC-1 cells were cultured in F-12K medium (Wisent, Saint-Jean-Baptiste, QC, Canada). All media were supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA). HLECs were obtained from ScienCell Research Laboratories and maintained in ECM (Gibco), which contained 5% FBS. All cells were maintained at 37 C in a humidified incubator with 5% CO 2 .

Popliteal lymphatic metastasis assay
All animal studies were carried out according to our previously published guidelines 42 and permitted by Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Nude BALB/c mice at 4 to 5 weeks old were obtained from the Experimental Animal Center (Guangzhou, P.R. China). The mice were divided randomly into groups, and 5 Â 10 6 UM-UC-3 cells transfected with circEHBP1-overexpressing vector or negative control (NC) vector were inoculated into the right footpad of each mouse. When the tumor reached 200 mm 3 , the mice were visualized using the IVIS spectral imaging system; the primary tumor and popliteal LNs were removed and then analyzed by IHC using anti-LYVE-1 antibodies (Abcam, Cambridge, UK). Images were visualized under a Nikon Eclipse Ti microscope (Nikon, Japan). Original images of excised popliteal LNs from the nude mice are shown in Figure S5.

Biotin-coupled probe RNA pull-down assay
To prepare the streptavidin-coated magnetic beads, the beads were blocked with 10 mg/mL bovine serum albumin (BSA) and yeast tRNA for 3 h on a rotator at 4 C and then incubated with an oligo probe or circEHBP1 probe for 2 h at room temperature. About 2 Â 10 7 UM-UC-3 or T24 cells were immobilized with 1% formaldehyde and lysed with lysis buffer, and then the beads containing pulldown probes were incubated with cell lysates overnight. Next, 50 mL of cell lysate was extracted as input, and quantitative real-time RT-PCR analysis was performed for target gene calculation. The probes used in the assay are shown in Table S4.

Further applied methods
Additional plasmids and siRNA transfection, lentiviral transduction, RNA preparation, quantitative real-time RT-PCR, IHC, gel electrophoresis analysis, RNase R treatment, northern blotting, actinomycin D experiment, CCK-8 and colony formation assay, HLEC tube formation assay, Transwell assay, nuclear and cytoplasmic fractionation experiment, FISH, co-localization of circEHBP1 and miR-130a-3p, dual-luciferase reporter assay, and ELISA are further described in the Supplemental methods. The antibodies used in this study are shown in Table S5.

Data Availability
RNA-sequence data have been deposited in the GEO database and can be accessed with GEO: GSE77661.

Statistical analysis
All statistical data are presented as the mean ± standard deviation from three experiments independently using GraphPad Prism version 8.0 (GraphPad, La Jolla, CA, USA). Kaplan-Meier analysis and the log-rank test were performed to assessed survival. The c 2 test was used to analyze the connection between circEHBP1 and the pathological parameters of patients with BCa. The differences in parameter variables between the two groups were estimated using two-tailed Student's t test or 1-way analysis of variance (ANOVA). A probability below 0.05 was used as an indicator of statistical significance.

DECLARATION OF INTERESTS
The authors declare no competing interests.